Atgam

Atgam (Anti-T Lymphocyte Immunoglobulin) is an immunosuppressive medication used to prevent organ rejection after transplants. This horse-derived immunoglobulin is administered intravenously and is manufactured by Pfizer Aps.

Atgam is primarily used to prevent rejection of kidney transplants. It works by suppressing the immune system's response to the transplanted organ. This medication is often considered when other immunosuppressive treatments have not been effective. Patients and healthcare providers may explore Atgam for its role in managing immune responses in transplant scenarios.

Common effects of Atgam may include fever, chills, and allergic reactions during or after administration. Some patients might experience fatigue or changes in blood pressure. These effects can vary and should be discussed with a healthcare professional.

Atgam should be administered under medical supervision due to its potent immunosuppressive properties. Patients with a history of allergic reactions to horse proteins should use this medication with caution. Regular monitoring is essential to manage potential side effects and ensure safety.

Atgam may interact with other immunosuppressive drugs, increasing the risk of infections or other complications. It is important to inform healthcare providers about all medications being taken to avoid adverse interactions. Alcohol and certain other substances may also affect the body's response to Atgam.